In brief, these results suggest that the S100A7/cPLA2/PGE2 signaling cascade generates an iTME through modulating the recruitment and plasticity of different immunosuppressive myeloid cells, especially TAMs in metastatic breast cancer, and therefore, disrupting this signaling mechanism may heighten the anti-tumor immune response. The gene discussed is S100A7; the disease is neoplasm.